Press Releases April 6, 2026 08:00 PM

Amneal to Report First Quarter 2026 Results on May 1, 2026

Amneal Pharmaceuticals Announces Q1 2026 Earnings Release Date and Webcast

By Derek Hwang AMRX
Amneal to Report First Quarter 2026 Results on May 1, 2026
AMRX

Amneal Pharmaceuticals, a diversified global biopharmaceutical company, will report its first quarter 2026 financial results on May 1, 2026, prior to market open, with a live webcast and conference call available for investors.

Key Points

  • Amneal will release Q1 2026 financial results on May 1, 2026, followed by an investor webcast and conference call.
  • The company is a diversified biopharmaceutical leader with a portfolio of approximately 300 complex, specialty and biosimilar medicines.
  • Amneal operates through segments including Affordable Medicines, Specialty branded treatments in neurology and endocrinology, and AvKARE distribution to federal, retail, and institutional customers.

BRIDGEWATER, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced that the Company will release its first quarter 2026 financial results on Friday, May 1, 2026, prior to market open. The Company will host an audio webcast at 8:30 a.m. ET.

The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com. Individuals may register for the webcast by clicking the link here. To access the call through a conference line, dial 1 (833) 461-5787 (in the U.S.) or for a list of toll-free international numbers, visit this here. The access code for the call is 458312872. A replay of the conference call will be posted shortly after the call.

About Amneal
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, New Jersey, is a diversified, global biopharmaceutical leader focused on expanding access to affordable and innovative medicines. Founded in 2002 by brothers and co-CEOs Chirag and Chintu Patel, Amneal was built on the belief that innovation only matters if it’s accessible. Today, Amneal has a diverse and growing portfolio of approximately 300 complex, specialty and biosimilar medicines, delivering over 160 million prescriptions each year, primarily in the United States. Our Affordable Medicines segment spans retail, injectable, and biosimilar products. Our Specialty segment provides branded treatments in neurology, including Parkinson’s disease and migraine, and endocrinology. Our AvKARE segment distributes pharmaceuticals and medical products to U.S. federal, retail, and institutional customers. For more information, visit www.amneal.com and follow us on LinkedIn.

Investor Contact
Anthony DiMeo
VP, Investor Relations
[email protected]


Risks

  • Financial results could be negatively impacted by market or regulatory factors affecting pharmaceutical sales and product approval.
  • The company's reliance on the U.S. market and healthcare regulations poses exposure to policy changes and reimbursement challenges.
  • Competition in the generic, specialty, and biosimilar medicine sectors could impact market share and profitability.

More from Press Releases

Fiverr Announces First Quarter 2026 Results Apr 29, 2026 Nayax to Report 2026 Q1 Earnings on May 12, 2026 Apr 28, 2026 Xunlei Filed Its Annual Report on Form 20-F for Fiscal Year 2025 Apr 28, 2026 Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Apr 28, 2026 Syntec Optics (Nasdaq: OPTX) Announces Pricing of $20 Million Underwritten Public Offering of Common Stock Apr 28, 2026